Breaking Up is Hard to Do: Lessons Learned from a Pharma-Free Practice Transformation

References

1. 1.↵
   1. May CD

   . Selling drugs by “educating” physicians. J Med Educ 1961;36:1–23.

   OpenUrlPubMedWeb of Science
2. 2.↵
   1. Gagnon MA,
   2. Lexchin J

   . The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;5:e1.

   OpenUrlCrossRefPubMed
3. 3.↵
   IMS Health. Total US promotional spend by type. 2011. Available from http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Promo_Spend_By_Type.pdf. Accessed March 26, 2013.
4. 4.↵
   1. Berenson A

   . Pfizer to cut its U.S. sales force by 20%. New York Times 2009. Available from http://www.nytimes.com/2006/11/28/business/28cnd-pfizer.html?_r=0. Accessed August 6, 2012.
5. 5.↵
   GlaxoSmithKline to cut 1,000 sales jobs in the U.S. New York Times 2008. Available from http://www.nytimes.com/2008/11/06/business/06glaxo.html. Accessed August 6, 2012.
6. 6.↵
   1. Blumenthal D

   . Doctors and drug companies. N Engl J Med 2004;351:1885–90.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   Bureau of Labor Statistics. Occupational outlook handbook [homepage]. Available from http://www. bls.gov/ooh/. Accessed March 13, 2013.
8. 8.↵
   1. Wazana A

   . Physicians and the pharmaceutical industry. JAMA 2000;283:373–80.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Brennan TA,
   2. Rothman DJ,
   3. Blank L,
   4. et al

   . Health industry practices that create conflicts of interest: a policy proposal for academic medical centers. JAMA 2006;295:429–33.

   OpenUrlCrossRefPubMedWeb of Science
10. 10.↵
    1. Brody H

    . The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 2005;3:82–5.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Brewer D

    . The effect of drug sampling policies on residents' prescribing. Fam Med 1998;30:482–6.

    OpenUrlPubMed
12. 12.↵
    1. Spurling GK,
    2. Mansfield PR,
    3. Montgomery BD,
    4. et al

    . Information from pharmaceutical companies and the quality, quantity, and cost of physicians' prescribing: a systematic review. PLoS Med 2010;7:e1000352.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Ross JS,
    2. Lackner JE,
    3. Lurie P,
    4. Gross CP,
    5. Wolfe S,
    6. Krumholz HM

    . Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota. JAMA 2007;297:1216–23.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Chimonas S,
    2. Patterson L,
    3. Raveis VH,
    4. Rothman DJ

    . Managing conflicts of interest in clinical care: a national survey of policies at U. S. medical schools. Acad Med 2011;86:293–9.

    OpenUrl
15. 15.↵
    1. Carpenter D JS.

    . A unique researcher identifier for the physician payments sunshine act. JAMA 2011;305:2007–8.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Rothman DJ,
    2. McDonald WJ,
    3. Berkowitz CD,
    4. et al

    . Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA 2009;301:1367–72.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Raad R,
    2. Appelbaum PS

    . Relationships between medicine and industry: approaches to the problem of conflicts of interest. Ann Rev Med 2012;63:465–77.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Cohen ML

    . Taming the sample closet. Fam Pract Manag 2006;13:43–6.

    OpenUrlPubMed
19. 19.↵
    1. Erickson S,
    2. Cullison S

    . Closing the sample closet. Fam Pract Manage 1995;1:43–7.

    OpenUrl
20. 20.↵
    1. Brown SR

    . Closing the sample closet. Fam Pract Manag 2006;13:16,author reply 21.

    OpenUrlPubMed
21. 21.↵
    1. Angell M

    . The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2005.
22. 22.↵
    1. Campbell EG,
    2. Rao SR,
    3. DesRoches CM,
    4. Iezzoni LI,
    5. Vogeli C,
    6. Bolcic-Jankovic D,
    7. Miralles PD

    . Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med 2010;170:1820–6.

    OpenUrlCrossRefPubMedWeb of Science
23. 23.↵
    Association of American Medical Colleges. Industry funding of medical education. Report of an AAMC tast force. June 2008 Available from https://members.aamc.org/eweb/upload/Industry%20Funding%20of%20Medical%20Education.pdf. Accessed March 13, 2013.
24. 24.↵
    1. Evans DV,
    2. Hartung DM,
    3. Andeen G,
    4. et al

    . One practice's experiment in refusing detail rep visits. J Fam Pract 2011;60:E1–6.

    OpenUrlPubMed
25. 25.↵
    1. Avorn J,
    2. Fischer M

    . ‘Bench to behavior': translating comparative effectiveness research into improved clinical practice. Health Aff (Millwood) 2010;29:1891–900.

    OpenUrlAbstract/FREE Full Text
26. 26.↵
    1. Mitka M

    . New physician education initiatives seek to remove the devil from the detailing. JAMA 2011;306:1187–8.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Gibbons RV,
    2. Landry FJ,
    3. Blouch DL,
    4. et al

    . A comparison of physicians' and patients' attitudes toward pharmaceutical industry gifts. J Gen Intern Med 1998;13:151–4.

    OpenUrlCrossRefPubMedWeb of Science